On July 9, Hebang Biology issued a reply announcement on the Shanghai Stock Exchange's Information Disclosure Regulatory Inquiry Letter on the 2024 Annual Report of Sichuan Hebang Biotechnology Co., Ltd. In the
announcement, Hebang Biology said it had decided to suspend/stop the follow-up investment of 10g W solar wafer project and float glass production line project.
Among them, Hebang Biology has invested about 340 million yuan in the 10GWN + ultra-high efficiency monocrystalline solar wafer project, and has completed the production capacity of about 1.5g WN-type silicon wafers. Based on the price fluctuation of the silicon wafer industry and the periodic capacity mismatch in the overall market of the photovoltaic industry , the company decided to suspend the follow-up investment in the remaining capacity in a prudent manner. The specific investment is as follows:
In addition, Hebang Biology also decided to stop the technical transformation projects and corresponding research and development activities of the float glass production line. It is understood that the R & D personnel of Hebang Bio-photovoltaic and Glass Plate have shrunk dramatically, with a total reduction of 38 people, leaving only one R & D personnel. In this regard, Hebang Biology explained that the main reason is that the glass business has made corresponding business strategy adjustments due to drastic changes in the downstream market.